GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Mirabegron (Myrbetriq)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The handbook includes historical dosing below GFR 15 and during dialysis. The selected U.S. adult tablet label does not recommend use below eGFR 15 or during hemodialysis; the handbook is not an override.

Check source scope before reading a dose

Renal Drug Handbook, fifth edition

Product / population
Historical 2019 reference; renal bands retain the book's own method labels.
Renal method
Not specified
Source revision
Not established
Retrieved
2026-09-05
Local review status
Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.
Handbook

Renal Drug Handbook, fifth edition

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical renal bands

GFR 30-60 mL/min: usual dose, or 25 mg with CYP3A inhibitors. At 15-29, the book lists 25 mg daily and avoidance with CYP3A inhibitors. It also lists 25 mg below 15, with the same interaction caution.

general-mirabegron:rdh5-663-1 · Source locator: Dose in renal impairment

Historical renal-replacement comments

The book considers removal unlikely across APD/CAPD, HD, high-flux HDF and CAV/VVHD, referring the first three to <15 and CAV/VVHD to 15-29.

general-mirabegron:rdh5-663-2 · Source locator: Dose in renal replacement

Source-specific limits

The selected U.S. adult tablet label does not recommend treatment below eGFR 15 or on hemodialysis. The book's below-15 and dialysis doses are historical source differences, not endorsed replacement protocols.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 663; PDF page 682
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
7fdc14e013014fab28634985209346ad764d335ccd9f949373e0b3a0fa685365

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=general-mirabegron&s1=rdh5-663&h1=ddddcae39eed9ac61f13c6b2ee434208195a675f4d7dad2e5d820c5d66dae992